ES2078642T3 - Vacuna recombinante contra la enfermedad de marek. - Google Patents

Vacuna recombinante contra la enfermedad de marek.

Info

Publication number
ES2078642T3
ES2078642T3 ES92201357T ES92201357T ES2078642T3 ES 2078642 T3 ES2078642 T3 ES 2078642T3 ES 92201357 T ES92201357 T ES 92201357T ES 92201357 T ES92201357 T ES 92201357T ES 2078642 T3 ES2078642 T3 ES 2078642T3
Authority
ES
Spain
Prior art keywords
disease
protein
vaccine against
recombinant vaccine
against marek
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92201357T
Other languages
English (en)
Inventor
Robin Wilson Morgan
Johannes Antonius Jo Claessens
Paulus Jacobus An Sondermeijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2078642T3 publication Critical patent/ES2078642T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTE INVENTO MUESTRA UN SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA UNA PROTEINA DE VIRUS DE LA ENFERMEDAD DE MAREK MD06. DICHA PROTEINA PUEDE UTILIZARSE PARA LA IMUNIZACION DE AVES DE CORRAL CONTRA LA ENFERMEDAD O INFECCION MDV. LA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA LA PROTEINA MDV MD06 PUEDE APLICARSE A LA PREPARACION DE LA PROTEINA MEDIANTE TECNICAS DE INGENIERIA GENETICA O PUEDE APLICARSE PARA LA PREPARACION DE VACUNAS PORTADORAS.
ES92201357T 1991-05-14 1992-05-13 Vacuna recombinante contra la enfermedad de marek. Expired - Lifetime ES2078642T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69946791A 1991-05-14 1991-05-14

Publications (1)

Publication Number Publication Date
ES2078642T3 true ES2078642T3 (es) 1995-12-16

Family

ID=24809465

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92201357T Expired - Lifetime ES2078642T3 (es) 1991-05-14 1992-05-13 Vacuna recombinante contra la enfermedad de marek.

Country Status (12)

Country Link
US (1) US6051404A (es)
EP (1) EP0513921B1 (es)
JP (1) JP3375347B2 (es)
AT (1) ATE126274T1 (es)
AU (1) AU654186B2 (es)
CA (1) CA2067469C (es)
DE (1) DE69203950T2 (es)
ES (1) ES2078642T3 (es)
GR (1) GR3017973T3 (es)
HU (1) HU218102B (es)
NZ (1) NZ242707A (es)
ZA (1) ZA923041B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369025A (en) * 1991-06-28 1994-11-29 The United States Of America As Represented By The Secretary Of Agriculture Recombinant fowlpox vaccine for protection against Marek's disease
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
WO1995021255A1 (en) * 1994-02-07 1995-08-10 Cornell Research Foundation, Inc. Compositions useful in controlling marek's disease
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
US6475770B1 (en) 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines
US7314715B2 (en) 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
PL2629794T3 (pl) * 2010-10-18 2017-10-31 Intervet Int Bv Szczepionka wektorowa z herpeswirusem indyków przeciwko grypie ptaków u drobiu
CN114540312B (zh) * 2022-03-16 2023-03-24 河南省农业科学院 一种血清1型马立克病病毒pp38单克隆抗体的制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854190T2 (de) * 1987-07-27 1996-03-28 Syntro Corp Attenuierte herpesviren, herpesviren, die für eine aminosäuresequenz kodierende fremde dns beeinhalten und sie enthaltende impfstoffe.
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体

Also Published As

Publication number Publication date
JP3375347B2 (ja) 2003-02-10
AU1624292A (en) 1993-03-11
DE69203950D1 (de) 1995-09-14
CA2067469A1 (en) 1992-11-15
ZA923041B (en) 1993-04-28
HU218102B (hu) 2000-06-28
ATE126274T1 (de) 1995-08-15
EP0513921B1 (en) 1995-08-09
HU9201590D0 (en) 1992-08-28
JPH05227973A (ja) 1993-09-07
GR3017973T3 (en) 1996-02-29
DE69203950T2 (de) 1995-12-21
AU654186B2 (en) 1994-10-27
HUT62330A (en) 1993-04-28
NZ242707A (en) 1994-03-25
US6051404A (en) 2000-04-18
CA2067469C (en) 2003-07-01
EP0513921A2 (en) 1992-11-19
EP0513921A3 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
BRPI9912663B8 (pt) vacina contra cáncer e polipeptìdeo.
DE3677494D1 (de) Virus-impfstoff.
DE69333468D1 (de) Schützende antikörper induzierende antigene aus plasmodium falciparum
ES2100240T3 (es) Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen.
ES2078642T3 (es) Vacuna recombinante contra la enfermedad de marek.
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
CA2066940A1 (en) Canine coronavirus subunit vaccine
BR9812240A (pt) Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica
DK0653489T3 (da) Coccidiosisvaccine til fjerkræ
IL97013A (en) Immunoreactive protein of an eimeria merozoite surface antigen, dna encodidng it, the production of the protein and its use as a vaccine
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
DK0709460T3 (da) Fjerkrævaccine imod coccidiosis
EP0612532A3 (en) Canine coronavirus vaccine from feline enteric coronavirus
DK0587636T3 (da) Fiskevaccine til Aeromonas salmonicida-infektion
ITRM910385A0 (it) Vaccini utilizzanti eritrociti come veicoli di antigeni.
Morgan et al. Recombinant vaccine against Marek's disease
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
TH23725A (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก
TH50271A3 (th) เพสทิไวรัสที่ไม่แผ่กระจาย
ATE366305T1 (de) Vogel-polyomavirus impfstoff in papageien

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513921

Country of ref document: ES